APYX Apyx Medical Corp

CIK 0000719135 50 ready 8-Ks latest August 7, 2026, 4:00 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 7, 2026, 4:00 PM ET

Top materiality 0.85

Event mix earnings ×22 · other_material ×11 · leadership ×5

Sentiment 17 pos · 12 neg · 21 neu

Latest earnings reported 2024-Q2

Executive change recent →

Recent 8-K filings for APYX

Highest-materiality recent filing

Apyx Medical Q3 revenue down 4% to $11.5M; cuts FY24 guidance; workforce –25%

November 8, 2024, 6:59 PM ET earnings materiality 0.85 negative item 1.01 item 2.02 item 2.03 item 3.02 item 5.02 item 8.01 item 9.01 ◈ executive_change ×4

Net loss $4.7M ($0.14/share) vs $4.6M YoY; adjusted EBITDA loss $2.4M.
Total revenue $11.5M (Advanced Energy -6% to $9.3M; OEM +3% to $2.2M).

Read filing →

August 7, 2026, 4:00 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01

Apyx shareholders approve 2026 Share Incentive Plan with 4M shares

Stockholders approved 2026 Share Incentive Plan; 16,186,776 for, 2,755,882 against, 3,276,000 abstain, 7,677,267 broker non-votes.
August 6, 2026, 4:09 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Apyx Medical Q2 revenue $13.9M (+22% YoY); Surgical Aesthetics up 28%; reaffirms FY guidance

Total revenue $13.9M vs $11.4M in Q2 2025; Surgical Aesthetics segment grew 28% to $12.4M.
July 24, 2026, 5:18 PM ET other materiality 0.20 neutral item 8.01 item 9.01

Apyx Medical reconstitutes board committees; Executive Chairman Vizirgianakis steps off all committees

Audit Committee: Lawrence J. Waldman (Chair), Minnie Baylor-Henry, Wendy Levine.
June 17, 2026, 4:05 PM ET leadership materiality 0.60 neutral item 1.01 item 9.01

Apyx Medical appoints Chairman Stavros Vizirgianakis as Executive Chairman; grants 450,000 RSUs

Stavros Vizirgianakis appointed Executive Chairman effective June 11, 2026; will lead strategic initiatives and investor engagement.
May 21, 2026, 4:23 PM ET other material materiality 0.30 positive item 8.01 item 9.01

Apyx Medical publishes clinical data showing 81.8% cellulite improvement with Avéli-Renuvion combination

22 patients received single-session treatment combining Avéli subcision and Renuvion helium plasma RF.
May 14, 2026, 8:05 AM ET other material materiality 0.45 positive item 8.01 item 9.01

Renuvion + liposuction shows higher satisfaction, lower revision rates in 113-patient study

Patients with Renuvion reported higher satisfaction with excess skin: Body-Q score 87.8 vs 73.8 (p=0.03).
May 11, 2026, 7:59 PM ET regulatory materiality 0.60 positive item 8.01 item 9.01

Apyx Medical receives FDA clearance for power liposuction on AYON Body Contouring System

Expanded FDA 510(k) clearance for AYON Body Contouring System to include power liposuction, a reciprocating cannula for efficient fat removal.
May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance

Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.
March 10, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M

Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.
January 12, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%

Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.
December 12, 2025, 6:59 PM ET other material materiality 0.00 neutral item 5.03 item 9.01 ◈ Governance Changes

Apyx Medical files Certificate of Amendment to delete Article EIGHTH from charter

Stockholders approved the amendment at the August 7, 2025 annual meeting.
November 19, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Apyx Medical prices $10M public offering of 2.76M shares at $3.62/share

Offering of 2,762,431 shares priced at $3.62 per share, with gross proceeds ~$9.4M.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M

Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).
August 13, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Apyx Medical annual meeting: directors elected, auditor ratified, say-on-pay approved, charter amended

All five director nominees elected with wide margins; broker non-votes ~6.8M.
August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M

Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.
May 13, 2025, 7:59 PM ET regulatory materiality 0.60 positive item 8.01 item 9.01

Apyx Medical receives FDA 510(k) clearance for AYON Body Contouring System

AYON is the first FDA-cleared all-in-one platform combining fat removal, contouring, tissue contraction, and electrosurgery.
May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M

Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.
April 29, 2025, 7:59 PM ET other material materiality 0.50 positive item 8.01 item 9.01

Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy

First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.
March 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Apyx Medical Q4 2024 revenue $14.2M (down 3% YoY); net loss narrows to $4.6M; submits AYON 510(k) ahead of schedule

Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).
February 6, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change

Apyx Medical names Shawn Roman COO with $305,760 base salary, bonus target ≥50%

Shawn Roman appointed COO effective Jan 28, 2025; base salary $305,760.52.
January 13, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ

Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).
January 6, 2025, 6:59 PM ET regulatory materiality 0.60 neutral item 8.01 item 9.01

Apyx submits 510(k) for AYON Body Contouring System; ahead of schedule

Submitted 510(k) premarket notification to FDA for AYON Body Contouring System.
November 8, 2024, 6:59 PM ET earnings materiality 0.85 negative item 1.01 item 2.02 item 2.03 item 3.02 item 5.02 item 8.01 item 9.01 ◈ executive_change ×4

Apyx Medical Q3 revenue down 4% to $11.5M; cuts FY24 guidance; workforce –25%

Net loss $4.7M ($0.14/share) vs $4.6M YoY; adjusted EBITDA loss $2.4M.
August 12, 2024, 7:59 PM ET other materiality 0.05 neutral item 5.07

Apyx Medical annual meeting elects all eight director nominees and ratifies auditor

Stockholders elected all eight director nominees; votes in favor ranged from 13.2M to 14.1M.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance

Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.
May 9, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 1.01 item 5.02 item 9.01 ◈ executive_change ×2

Apyx Medical appoints Stavros Vizirgianakis as Chairman; founder Andrew Makrides retires after 40+ years

Andrew Makrides retired as Chairman effective May 7, 2024, after serving since 1982.
May 9, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Apyx Medical Q1 revenue $10.2M (-16% YoY); net loss $7.6M; Chairman retires

Total revenue $10.2M (-16% YoY); Advanced Energy $7.5M (-23%); OEM $2.8M (+14%).
March 21, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Apyx Medical Q4 revenue up 16% to $14.7M; net loss widens to $9.6M; FY2024 guidance implies potential revenue decline

Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.
February 21, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Apyx Medical announces Renuvion study shows significantly fewer adverse events vs InMode RF

Retrospective study of 450+ patients: 229 Renuvion vs 236 InMode Bipolar RF; statistically fewer adverse events (p<.0001).
January 22, 2024, 6:59 PM ET other material materiality 0.55 positive item 8.01 item 9.01

Apyx Medical publishes 483-patient study showing Renuvion safety after liposuction across multiple body areas

Analysis of 483 patients (1,184 body areas) found no new or increased risks vs. liposuction alone.
January 8, 2024, 6:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Apyx Medical reports preliminary Q4 rev $14.2-14.6M (+13-16% YoY); FY rev $51.9-52.3M (+17-18%)

Total Q4 revenue $14.2-14.6M, growth 13-16% YoY; Advanced Energy $11.9-12.3M (+12-16%).
November 28, 2023, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Apyx Medical appoints Matthew Hill as CFO effective Dec 4, 2023

Matthew Hill appointed CFO, effective Dec 4, 2023, succeeding Tara Semb who departed Nov 9.
November 16, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

CFO Tara Semb to depart Apyx Medical; successor identified but not named

CFO Tara Semb leaving to pursue other opportunities, effective upon appointment of successor.
November 9, 2023, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

Apyx Medical Q3 revenue up 31% to $12.0M; cuts FY2023 revenue guidance sharply

Q3 Advanced Energy revenue $9.8M (+39%); total revenue $12.0M (+31%); net loss $4.6M improved 20% YoY.
November 9, 2023, 6:59 PM ET debt materiality 0.65 neutral item 1.01 item 1.02 item 2.03 item 9.01 ◈ Material Agreements ×2◈ Debt Financings

Apyx Medical enters up to $45M debt facility with Perceptive, replaces MidCap loan

Initial $37.5M funded Nov 8; up to $7.5M delayed draw available through Dec 31, 2024 subject to conditions.
August 16, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Apyx Medical annual meeting elects 8 directors, ratifies auditor, approves 2023 incentive plan

All 8 director nominees elected, including Andrew Makrides (18.7M for, 224K against) and Charles Goodwin (19.0M for, 21K against).
August 10, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Apyx Medical Q2 revenue up 32% to $13.6M, net loss narrows 82% to $1.0M, reaffirms FY2023 guide

Advanced Energy revenue rose 40% YoY to $11.7M; OEM revenue fell 4% to $1.8M.
May 11, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Apyx Medical Q1 revenue $12.1M (-3% YoY); raises FY2023 guidance; FDA updates Safety Communication

Total revenue $12.1M (-3% YoY); Advanced Energy $9.7M (-10%); OEM $2.5M (+46%).
April 18, 2023, 7:59 PM ET other material materiality 0.25 neutral item 1.01 item 9.01 ◈ Material Agreements

Apyx Medical extends property sale inspection period to May 4, 2023, closing to May 8

Amendment extends Inspection Period for Clearwater facility sale to 5:00 p.m. ET on May 4, 2023.
March 16, 2023, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Apyx Medical Q4 2022 revenue down 25% to $12.6M; net loss $6.0M; guides 2023 rev $58-61M

Q4 total revenue $12.6M (-25% YoY); Advanced Energy segment $10.5M (-30% YoY); OEM $2.1M (+15% YoY).
March 15, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01 ◈ Material Agreements

Apyx Medical sells headquarters for $7.65M in sale-leaseback; expects $6.7M net proceeds

Sale price $7,650,000 for Clearwater, FL facility; net proceeds estimated at ~$6.7M after taxes and fees.
February 24, 2023, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings ×2◈ Material Agreements

Apyx Medical enters $35M credit facility with MidCap Financial; initial $10M funded

Up to $25M senior secured term loan (initial $10M funded) plus $10M revolver; matures Feb 1, 2028.
January 10, 2023, 6:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

Apyx Medical reports preliminary Q4 revenue $12.1-12.5M (-26-28% YoY); full year $44-44.4M (-8-9%)

Advanced Energy rev Q4 $10.1-10.5M (-30-33% YoY); OEM rev $2.0M (+12% YoY).
November 10, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Apyx Medical Q3 revenue down 23% YoY; cuts full-year 2022 guidance

Total revenue $9.1M (-23% YoY); Advanced Energy revenue $7.1M (-31% YoY).
August 17, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Apyx Medical announces annual meeting results; all director nominees elected, auditor ratified, say-on-pay approved

All eight director nominees elected; votes ranged from 15,768,279 for Minnie Baylor-Henry to 15,909,798 for Wendy Levine.
August 11, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Apyx Medical Q2 revenue down 8% YoY; narrows 2022 guidance

Total revenue $10.3M (-8% YoY); Advanced Energy revenue $8.4M (-16% YoY), OEM $1.9M (+55%).
July 18, 2022, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Apyx Medical receives FDA 510(k) clearance for Renuvion to treat loose skin on neck and chin

FDA clearance for Renuvion APR Handpiece for subcutaneous procedures to improve appearance of lax skin in neck and submental region.
June 13, 2022, 7:59 PM ET litigation materiality 0.65 negative item 8.01

Apyx Medical named in securities class action over off-label product statements

Plaintiff William Hattaway filed securities class action in Middle District of Florida on June 6, 2022.
May 26, 2022, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Apyx Medical gets FDA 510(k) clearance for Renuvion dermal resurfacing handpiece

Clearance for treatment of moderate to severe wrinkles, limited to Fitzpatrick skin types I–III.
May 12, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Apyx Medical Q1 revenue up 45% to $12.5M, net loss widens, guidance narrowed

Revenue $12.5M (+45% YoY); Advanced Energy $10.8M (+41%), OEM $1.7M (+72%).

Executive changes

Appointed

Shawn Roman

Chief Operating Officer

APYX · Apyx Medical Corp

Effective: 2025-01-28
Filed: February 6, 2025, 6:59 PM ET

following the prior announcement that it had appointed Shawn Roman as its Chief Operating Officer

Departed

Michael Geraghty

Director

APYX · Apyx Medical Corp

Effective: 2024-11-04
Filed: November 8, 2024, 6:59 PM ET

On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.

Departed

John Andres

Director

APYX · Apyx Medical Corp

Effective: 2024-11-04
Filed: November 8, 2024, 6:59 PM ET

On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.

Appointed

Shawn D. Roman

Chief Operating Officer

APYX · Apyx Medical Corp

Effective: 2024-11-06
Filed: November 8, 2024, 6:59 PM ET

On November 6, 2024, the Board appointed Shawn D. Roman as the Chief Operating Officer of the Company, effective immediately.

Departed

Craig Swandal

Director

APYX · Apyx Medical Corp

Effective: 2024-11-04
Filed: November 8, 2024, 6:59 PM ET

On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.

Departed

Andrew Makrides

Chairman of the Board

APYX · Apyx Medical Corp

Effective: 2024-05-07
Successor: Stavros Vizirgianakis
Filed: May 9, 2024, 7:59 PM ET

On May 7, 2024, Andrew Makrides announced his retirement as a director and Chairman of the Board, effective on the same date.

Appointed

Stavros Vizirgianakis

Director and Chairman of the Board

APYX · Apyx Medical Corp

Effective: 2024-05-07
Filed: May 9, 2024, 7:59 PM ET

On May 7, 2024, the Board appointed Mr. Vizirgianakis to serve as a director and Chairman of the Board, to fill the vacancy created by the retirement of Andrew Makrides.

Appointed

Matthew Hill

Chief Financial Officer

APYX · Apyx Medical Corp

Effective: 2023-12-04
Filed: November 28, 2023, 6:59 PM ET

On November 28, 2023, Apyx Medical Corporation (the “Company”) announced that it had appointed Matthew Hill as its Chief Financial Officer, effective December 4, 2023 (the “Effective Date”).

Departed

Tara Semb

Chief Financial Officer

APYX · Apyx Medical Corp

Filed: November 16, 2023, 6:59 PM ET

On November 9, 2023, Apyx Medical Corporation (the “Company”) and Tara Semb, Chief Financial Officer, announced that Ms. Semb would be leaving the Company in order to pursue other opportunities.

Appointed

Wendy Levine

Director

APYX · Apyx Medical Corp

Effective: 2021-08-25
Filed: August 30, 2021, 7:59 PM ET

On August 24, 2021, the Board of Direct ors (the “Board”) of Apyx Medical Corporation (the “Company”) appointed Wendy Levine to serve as a director of the Company, expanding its Board to eight (8) directors, effective August 25, 2021.

Earnings & guidance

2024-Q2 EPS reported -$0.41 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

17 positive 12 negative 21 neutral

source · APYX on sec.gov